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Cell-in-Cell Structures in the Liver:
A Tale of Four E’s
Scott P. Davies1, Lauren V. Terry1, Alex L. Wilkinson1 and Zania Stamataki1,2*
1 Centre for Liver and Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham,
Birmingham, United Kingdom, 2 NIHR Birmingham Liver Biomedical Research Centre, University Hospitals Birmingham NHS
Foundation Trust, Birmingham, United Kingdom
The liver is our largest internal organ and it plays major roles in drug detoxification
and immunity, where the ingestion of extracellular material through phagocytosis is a
critical pathway. Phagocytosis is the deliberate endocytosis of large particles, microbes,
dead cells or cell debris and can lead to cell-in-cell structures. Various types of cell
endocytosis have been recently described for hepatic epithelia (hepatocytes), which are
non-professional phagocytes. Given that up to 80% of the liver comprises hepatocytes,
the biological impact of cell-in-cell structures in the liver can have profound effects in liver
regeneration, inflammation and cancer. This review brings together the latest reports on
four types of endocytosis in the liver -efferocytosis, entosis, emperipolesis and enclysis,
with a focus on hepatocyte biology.
Keywords: cell-in-cell, liver, efferocytosis, entosis, emperipolesis, enclysis, cancer, regeneration
INTRODUCTION
Cell-in-cell (CIC) structures are formed when a whole cell resides inside the cytoplasm of
another, and they have been observed for decades in various contexts. The best characterized
CIC mechanism is known as efferocytosis, the clearance of dead or dying cells by professional
and non-professional phagocytes (1–9). Yet, CIC structures, in which the internalized cell remains
viable, have been observed for over a century (10). Recent work has provided evidence for the
role of hepatocytes, the principal parenchymal cell within the liver, in several of these processes:
efferocytosis (1), live cell internalization events including suicidal emperipolesis (11), entosis (12)
and enclysis (13) (Table 1). Although the immediate consequences of dead and live cell capture
have been investigated, the biological implications and impact on clinical outcomes remain
to be elucidated.
The liver receives 75% of its blood supply from the gastrointestinal tract via the hepatic portal
vein (14). As such, it is persistently challenged by toxic substances and microbial- or food-derived
antigens. Not only must the liver function to detoxify and neutralize harmful products it is exposed
to, it must also maintain an immunotolerising environment so as not to initiate inappropriate
immune responses to commensal microbes and food antigens. Nonetheless, the liver must retain
the ability to mount a rapid immune response in the case of infection. The role of the liver in
immunity is well-established (15), and the cells residing within it are finely tuned to maintain the
balance between immunotolerance and immunogenicity. If this balance is perturbed and tolerance
is breached, liver disease can develop due to hepatocyte damage during inflammation.
Chronic liver diseases follow a common pathway of progression independently of etiology.
Repeated liver injury results in fibrosis, cirrhosis and ultimately, end-stage disease leading to
liver failure, the only viable treatment option for these patients is liver transplantation, which is
associated with significant pitfalls including organ shortage and graft rejection. Since liver disease
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TABLE 1 | The mechanism of cell-in-cell structures.
Enclysis Emperipolesis Efferocytosis Entosis Macropinocytosis
Host cells Hepatocytes (13) Thymic Nurse
Cells (92)
Megakaryocytes
(93)
Hepatocytes
(suicidal
emperipolesis) (11)
Professional and
non-professional
phagocytes (5, 94,
95)
Trophoblast
cells (96)
Cancer cells (12, 65) All cell types (97)
Cargo CD4+ T cells. Treg Thymocytes Neutrophils (98) CD8+ T cells Cell corpses Luminal
Epithelium
Cancer cells Natural
Killer (NK)
cells (65)
Large amounts of
solutes
Invasion Yes Yes Yes Yes No ? Yes Yes N/A
Fate Deletion (Treg),
Escape (non-Treg)
MHC
restriction:
Selection or
deletion (99)
Egress Deletion Digestion Non-apoptotic cell death Apoptosis Digestion
Host
plasma
membrane
Lamellipodia, Blebs
(localized)
Ruffles
(localized) (99)
Protrusions No ruffling Ruffles (localized) ? Blebs ? Ruffles, blebs,
lamellipodia (69)
Known
adhesion
molecules
ICAM-1,
beta-catenin
? ICAM-1, LFA-1,
Ezrin
? Cell-type
dependent
E-cadherin, beta-catenin E-cadherin,
ICAM-2,
Ezrin
None
Inhibitor
sensitivity
Cyt D, Lat A, (actin
polymerization),
Anti-ICAM-1
Colchicine,
Jasplakinolide
(cytoskeleton)
(100)
Cyt D, Lat A,
Anti-ICAM-1,
anti-LFA-1
Wortmannin (PI3K)
(11)
Wortmannin
(cell-specific)
H-1152, Y-27632(Rho Kinases) Ezrin
siRNA,
E-cadherin
siRNA,
EGTA
(Ca2+
chelation)
EIPA (NHE-1) (101),
Blebbistatin
(Myosin II) Cyt D
The best-characterized process is efferocytosis, where multiple receptors have been identified, however, only one receptor is known for hepatocytes (ASGR1). Receptors unique to entosis, emperipolesis or enclysis
have not been identified.
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continues to increase worldwide (16) there is an unmet clinical
need to develop novel therapies that will alleviate chronic
inflammation, prevent fibrosis or boost liver immunity in the
context of viral infection and primary or metastatic liver cancer.
Hepatocytes constitute an attractive target for therapy in these
patients, because (i) they are uniquely found in the liver, (ii)
they drive regeneration in injury, (iii) they are the focus of
infection or malignancy in hepatocellular carcinoma, (iv) they are
a natural destination for drug absorption, and (v) unlike targeting
immune cells, hepatocyte-directed therapies are unlikely to cause
systemic immunosuppression or autoimmunity. We propose that
targeting CIC structures has the potential to lead to clinical
benefit for patients with liver diseases.
EFFEROCYTOSIS
The capture and deletion of dying cells by efferocytosis (from
effere, Latin for “to take to the grave,” “to bury”), a specialized
form of phagocytosis, is a crucial process for the liver with
important biological impact (1). The liver is inundated with
infiltrating immune cells that are destined to die by apoptosis
and be digested by liver cells (17). The frequent turnover of
hepatocytes, associated with the detoxification of waste products,
further contributes to the dead cell burden faced by the liver.
Failure to clear these cell corpses can spell disastrous immune
consequences, including premature inflammatory responses and
an increased risk of autoimmune disease (8).
To prevent the build-up of cellular debris, the cellular
composition of the liver is uniquely prepared, it is frequented
by monocyte-derived macrophages and possesses a specialized
resident macrophage population known as Kupffer cells, which
arise following signals from liver-resident cells (9, 18). Aside
from these “professional phagocytes,” liver- parenchymal and
non-parenchymal cells can also capture and delete dying cells.
These “non-professional” populations include hepatic sinusoidal
endothelial cells (HSECs), biliary epithelial cells (BECs), stellate
cells and hepatocytes (Figure 1) (3, 4, 6, 7). As such, the
liver is universally prepared to rapidly clear cell corpses, thus
maintaining its immune tolerance.
An astute adaptation of the liver to manage the persisting need
to clear dying cells is for its principal cell type, the hepatocyte,
to be adept at efferocytosis (1). Hepatocytes are epithelia tasked
with drug detoxification and can undergo necrotic cell death
in the process, thus neighboring hepatocytes are most likely to
make first contact with a dying cell. Hepatocyte efferocytosis
was first described in 1952, when Rosin and colleagues observed
the presence of erythrocytes within the cytoplasm of hepatocytes
(2). This was later ratified by Dini et al., who showed that
hepatocytes could also engulf apoptotic cells (3). The same
investigation suggested a role for asialoglycoprotein receptor 1
(ASGR1) in the recognition of these cells. Experiments conducted
in our group has further confirmed hepatocyte ability to engulf
necrotic cells in health and in cancer (1, 13). Other cells
which have this capability generally require alternative, more
improvisational molecular mechanisms to capture necrotic cells,
compared to those known for apoptotic cell capture (5, 20).
FIGURE 1 | Hepatocytes are important efferocytes. Comprising up to 80% of
the liver mass, hepatocytes engulf apoptotic and necrotic cells via the
asialoglycoprotein receptor (ASGR1) (3), and rapidly degrade them. This
process may supply the liver with nutrients while maintaining homeostasis by
eliminating pro-inflammatory cell debris. CIC structures can also lead to failure
of cytokinesis (19) and this can impact hepatocyte ploidy.
Hepatocytes can both remove and replenish areas of necrotic
sheets associated with disease-related hepatotoxicity, and drive
regeneration during injury (21–23).
In contrast to the liver’s professional phagocyte populations,
the mechanisms by which hepatocytes clear dead cells are poorly
understood. There are few candidate receptors, in addition
to ASGR1, by which hepatocytes may recognize and capture
dying cells. The consequences of efferocytosis for the hepatocyte
have also not been widely explored. The hepatocyte would be
granted nutrients from the lysosomal digestion of captured cells.
Hepatocytes may also acquire increased genetic diversity at the
cellular level through efferocytosis. Efferosomes may physically
impede cytokinesis, causing the engulfing hepatocyte to become
multinucleate, as seen in breast cancer cells with CIC structures
(12). Increased genetic diversity amongst hepatocytes has been
shown to increase the ability of the liver to adapt and regenerate
in response to a wider variety of insults (24, 25). Efferocytosis may
be a mechanism which accelerates this phenomenon, although
this may also increase the risk of contracting mutations associated
with the onset of hepatocellular carcinoma (HCC). Although
hepatocyte multinucleation is both frequent and tolerated in
the liver, particularly in older individuals (26, 27), chronic
efferocytosis resulting from disease-associated necrosis may
promote the acquisition of oncogenic mutations. As the onset
of HCC is rarely spontaneous and frequently associated with
chronic liver disease, increased hepatocyte efferocytosis may
represent a risk factor for its onset.
Dysregulation of efferocytosis in the liver can lead to
disease development. This has been exemplified in the case
of macrophage clearance, knockout mice lacking hepatic
macrophages that express the dead cell scavenger receptor,
MerTK, showed exasperated damage when treated with
acetaminophen (APAP) (28). More recently it was demonstrated
that carbon tetrachloride-treated glycoprotein NMB (gpnmb)
KO mice, whose macrophages lack the ability to process
internalized cells, showed greater activation of pro-fibrotic
myofibroblasts (29). It is also likely that the dysregulation of
hepatocyte efferocytosis may contribute to the pathogenesis of
other chronic liver diseases. Autoantibodies against ASGR1 have
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been detected in patients with autoimmune hepatitis (30, 31).
Additionally, ethanol-treated rat hepatocytes were shown to be
defective in ASGR1-mediated efferocytosis (32).
The effects of aging and the accompanying immune paresis
must be considered in liver homeostasis, specifically regarding
the clearance of apoptotic and necrotic cells. In both aging
and chronic liver disease, there is an accumulation of senescent
cells, which produce senescence-associated secretory phenotype
(SASP) factors. SASP factors include pro-inflammatory cytokines
and growth factors, that have been noted to alter the local
microenvironment and induce paracrine senescence and in turn,
immuno senescence (33–35). One characteristic of immune
senescence is the reduced capacity of a cell to phagocytose, which
may contribute to persistent inflammation in older individuals,
termed “inflammageing” and lead to defective clearance and
resolution of inflammation (36, 37).
Whilst little is understood about hepatocyte efferocytosis
in terms of aging, several in vivo studies have shown an
age-associated decline in macrophage efferocytosis in other
tissue types. For example, one study observed that peritoneal
macrophages from aged (24-month old) mice had an impaired
ability to efferocytose apoptotic Jurkat cells, compared to 2-
month old, young mice (38). This result was similarly observed
by Linehan et al., whom proceeded to transplant young (8 to
12-week-old mice) peritoneal macrophages into aged (15 to 20-
month-old mice) peritoneal space (39). The transplanted, young
macrophages in fact exhibited a diminished ability to efferocytose
post-transplantation, suggesting that the microenvironment lead
to alterations in the efferocytic ability. Additionally, there was
a decline in the ability of alveolar macrophages to efferocytose
neutrophils in aged mice, which may contribute to lung damage
(40). Based on links drawn between diminished efferocytic
capacity and old age, it is logical to infer that hepatocytes could
be subjected to similar pressures from aging and this warrants
further investigation.
Further understanding into the mechanisms of hepatocyte
efferocytosis will likely provide opportunities for promoting
dead cell clearance and thus preventing immature inflammatory
responses in the liver.
ENTOSIS
For over a century, CIC structures in which viable cells
are internalized into other cells have been reported (10,
41, 42). Live cells have been shown to invade or be
engulfed by host cells of non-phagocytic origin. Unlike
with efferocytosis, which consistently targets cell corpses
for lysosomal degradation, these cells can remain viable
within vacuole-like structures for long periods and succumb
to variable outcomes depending on the context. Although
the molecular mechanisms for most examples of live CIC
formation generally remain poorly understood, several
processes are well-described in the literature. One of
these is known as entosis (εντóς , inside, into, within)
(Figure 2) (41, 43).
In 2007, Overholtzer and colleagues reported that extracellular
matrix detachment of cancer cells could promote CIC formation
via contractile forces associated with adherens junction
formation. This process involved junctional proteins, E-cadherin
and β-catenin, and was dependent on actomyosin contractility
mediated by Rho-associated coiled-coil-containing protein
kinase (ROCK) activity in the target cell specifically (12).
This finding, coupled with time-lapse microscopy of CIC
formation, was strongly suggestive of target cell invasion as
opposed to engulfment and has since been confirmed in several
studies (44, 45).
The plasma membrane is the primary site for initiating
CIC formation. Plasma membrane blebbing and polarized actin
dynamics have been suggested as drivers of entotic invasion
(45), with a recent study demonstrating the requirement
for the myocardin-related transcription factor-serum response
factor (MRTF-SRF) pathway and subsequent sustained ezrin-
dependent plasma membrane blebbing (44). Furthermore, in
addition to the requirement for adherens junctions (12, 46,
47), studies have shown that the composition of the plasma
membrane play a role in entosis. Both liposomes and cholesterol
were shown to inhibit CIC formation, presumably by hindering
myosin light chain phosphorylation and thus actomyosin
contractility (48).
FIGURE 2 | Entosis in neoplastic hepatocytes. We recently showed that hepatocellular carcinoma cells were able to engulf their live neighbors by entosis (13).
Entosis is an important disease pathway in cancer epithelia involving E-cadherin and β-catenin (12). Tumor cells that detach from matrix are prone to entosis, and
further research is necessary to measure its implications in patients with hepatocellular carcinoma.
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The fate of the internalized cell is variable, most succumb to
non-apoptotic cell death and lysosomal degradation, although
some target cells occasionally undergo division or release (12,
43, 49–51). Thus, the biological consequences of entosis and
the impact on tumor biology remain controversial (52). Since
degradation of target cells by neighboring cancer cells has the
potential to limit tumor growth, then perhaps entosis represents
an intrinsic tumor suppressor mechanism, by which metastatic
cancer cells that become detached from matrix are eliminated.
Yet, adherent epithelial cells can also undergo entosis, a process
driven by mitosis and negatively regulated by cell cycle protein
Cdc42 (46). Furthermore, tumor cell cannibalism could promote
host cell survival by providing nutrients to those which lack
vascular access (53). In support of this, Overholtzer’s group later
demonstrated that entosis is induced in adherent cells by glucose
starvation, in a manner requiring activity of target cell AMP-
activated protein kinase (AMPK) (54). The ability of cancer
cells to adapt to starvation by performing entosis and enabling
nutrient recovery would confer metabolic advantage of malignant
cells, thereby promoting progression of more aggressive tumors.
Indeed, it has been proposed that there is direct competition
between cancer cells, dictated by mechanical deformability and
subsequent entosis, thus ensuring the survival of the most
adapted tumor cells (55). These findings highlight the importance
of the tumor microenvironment in regulating intracellular
signaling pathways that mediate entosis and tumor survival.
The clinical impact of entosis in hepatocellular carcinoma has
not been investigated. Similarly to observations made in other
epithelial cells, we reported recently that hepatomas cultured
in 2D were also capable of engulfing their neighbors (13).
The vesicle that housed the internalized cell was enriched in
E-cadherin, suggesting that this was another example of entosis
(Figure 2). It is not yet clear if non-neoplastic hepatocytes
perform entosis. Regardless, liver cancers may benefit from
entosis as a source of adaptation and nutrition. Given that
there is no effective therapy and the incidence of hepatocellular
carcinoma is increasing in the West (56), targeting entosis may
prove to be of clinical value.
EMPERIPOLESIS
Emperipolesis is a term coined by Humble et al. (57) and used
to describe the movement of live cells following internalization
(“inside-round-about wandering”) (Figure 3) (57). It has been
proposed that whilst CIC and emperipolesis should be used
generically to describe the process of cell movement associated
with CIC structures, cannibalism and entosis should be used
to refer to mechanisms of CIC formation specifically (10, 41).
Cell-in-cell structures, or emperipolesis, have long been observed
by histopathologists in several types of chronic liver disease.
Emperipolesis is increased in autoimmune hepatitis (58, 59)
and chronic viral infection (60, 61), suggesting a potential
role in liver injury or T cell clearance (62, 63). The precise
physiological and pathophysiological role of emperipolesis,
however, remains elusive.
The first demonstration of a physiological role for
emperipolesis in the liver was reported by Bertolino and
FIGURE 3 | Suicidal Emperipolesis. The seminal work by Benseler et al.
provided the first evidence for a biological role of the cell-in-cell structures
described as emperipolesis, where immune cells were engulfed alive by
hepatocytes (11). In this study, autoreactive CD8+ T cells were deleted by
suicidal emperipolesis in the liver. The mechanism of capture is not
understood, however, perturbation of this process led to breach of liver
tolerance in mice.
colleagues in 2011. They defined a mechanistically distinct
type of emperipolesis known as suicidal emperipolesis, in which
autoreactive CD8+ T lymphocytes actively invade hepatocytes
and undergo lysosomal degradation (11, 64). Inhibition of this
process by wortmannin led to intrahepatic accumulation of
autoreactive cells and a breach of tolerance. Wortmannin-treated
mice developed immune-mediated hepatitis 3 days post-infusion
with autoreactive CD8+ T cells, as determined by raised alanine
aminotransferase levels and histological liver damage. The
authors therefore proposed this as a mechanism of extrathymic
regulation for maintaining immune tolerance within the liver.
There is also evidence for a pathophysiological role of CIC
structures. Emperitosis, another form of emperipolesis, was the
name initially given to natural killer (NK) cell invasion of
tumor cells and subsequent programmed cell death. Like entosis,
emperitosis also requires cadherins, Rho/ROCK proteins and
ezrin (65, 66). In contrast to entosis, NK cells succumb to
caspase-3-mediated apoptosis, which was attributed to granzyme
B accumulation within the vacuole (65). This process has
also been extended to human cytotoxic regulatory T cell line,
HOZOT, which actively penetrate cancer cell lines but not
cells of non-neoplastic origin (67). It is therefore conceivable
that emperitosis of cytotoxic immune cells serves as one of
the many mechanisms employed by cancer cells to evade
immune surveillance. Furthermore, a recent study showing
that internalization of anti-fibrotic NK cells in HBV cirrhotic
patients is transforming growth factor-β-dependent and may
represent a novel mechanism of fibrogenesis (68). Further work is
required to fully elucidate the molecular mechanisms of suicidal
emperipolesis, which may allow therapeutic targeting in the
context of liver transplantation, autoimmune disease and viral
hepatitis. Nevertheless, the evidence that this process is distinct
from other CIC mechanisms is compelling, and is one example of
the complex pathways which can underlie CIC formation.
ENCLYSIS
We have recently reported a distinct cell capture process within
the liver termed enclysis (Eγκλε ωε´γ- (ε´v-) + κλε ω, to enclose,
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to confine, to keep in captivity), in which live CD4+ T cells are
captured by hepatocytes (Figure 4) (13). This process occurred
in vitro, in primary human hepatocytes and in hepatoma cells
(Huh-7 and HepG2 cells), and ex vivo within patient liver
samples. T cells were also found to reside within hepatocytes
in vivo as shown in 30 µm-thick sections from cirrhotic patients.
Whilst intercellular adhesion molecule-1 (ICAM-1) facilitated
early T cell adhesion to hepatocytes, the ligands for ICAM-1
are not distinct to CD4+ T cells and therefore this adhesion
molecule does not explain enclysis specificity. Interestingly,
adhesion molecule and junctional protein, β-catenin, selectively
associated with the enclytic vesicle, in contrast to the efferosome
(phagosome containing dead cell) which showed no β-catenin
localization. Despite both entosis and enclysis involving
formation of membrane blebs (13, 44, 45), enclysis was
distinguished from entosis by the lack of E-cadherin association
with the enclytic vesicle. Notably, instances of entosis were
observed between Huh-7 hepatoma cells, where a clear
localization of E-cadherin was apparent. The lack of requirement
for the RhoA/ROCK pathway, similar to suicidal emperipolesis,
provides a further distinction of enclysis and entosis. Enclysis
resembles macropinocytosis, in that there are significant
membrane alterations during cell capture events including
ruffling, blebs and lamellipodia formation (13, 69), which is in
contrast to emperipolesis where these membrane protrusions
are absent (63). Furthermore, the wortmannin-insensitivity of
enclysis further defines this process as mechanistically distinct,
compared with emperipolesis which is abrogated by wortmannin
treatment (11).
Whilst CD4+ T cells were specifically targeted over CD8+
T cells and CD20+ B cells, Tregs were three times more
likely to be engulfed than non-Treg cells. Vesicles containing
Tregs readily acidified with cells undergoing degradation via the
lysosomal pathway, unlike non-Tregs, which survived for long
periods and remained connected to the extracellular space via
the endocytic pathway. Moreover, FOXP3+ Tregs were more
frequently found within hepatocytes than Tbet+ effector cells,
in both donor livers surplus to clinical requirement and liver
explants from end-stage disease patients (13). Thus, we propose
enclysis as a novel immunomodulatory pathway within the liver
that could offer therapeutic opportunities to toggle inflammation.
But why would hepatocytes possess the ability to target Tregs for
degradation when an integral function of the liver is to maintain
immunotolerance? Although this seems counter-intuitive, given
the previous studies which have evidenced a role for the liver in
maintaining peripheral immune tolerance (70), it is conceivable
that enclysis could act as a biological switch, preventing the liver
from becoming “immunoblind”. The ability of hepatocytes to
control local T cell populations and modulate ratios of regulatory
and effector cells may represent an intrinsic mechanism by
which the liver can rapidly respond to its local inflammatory
environment. The stimuli and endogenous regulators of enclysis,
however, are yet to be defined.
Identification of selective modulators of enclysis may offer
opportunities for therapeutic intervention. On one hand,
inhibition of Treg cell capture and/or degradation may be
successful in situations where it is desirable to enrich local
Treg populations and dampen inflammation. Indeed, research
surrounding Treg cell-based therapy is ongoing (71–75),
and combination with pharmacological inhibitors of enclysis
may show promise for several indications, including chronic
inflammation and to promote immunotolerance following organ
transplantation. Alternatively, in the context of cancer, boosting
Treg sequestration or modulating release of effector T cell subsets
may be beneficial to enhance tumor immunogenicity (76).
IMPLICATIONS AND FUTURE
PERSPECTIVES
The impact of cell-in-cell structures on the host cell biology has
only recently been investigated. Phagocytosed cells that enter the
phagocyte as apoptotic cells or cellular debris, and also engulfed
live cells that may subsequently die inside endosomes, can present
an added source of nutrients. However, CIC may have longer-
lasting implications on the host cell.
FIGURE 4 | Enclysis in health and in hepatocellular carcinoma. Enclysis is the enclosure and lysis of regulatory T cells (Treg) by hepatocytes and hepatocyte cancer
cells (13). We showed that Treg cells were captured preferentially compared to non-regulatory CD4+ T cells, and also suffered a different fate, as non-regulatory T
cells often survived hepatocyte entry.
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FIGURE 5 | Cell-in-cell structures in healthy and neoplastic hepatocytes. Efferocytosis (apoptotic or necrotic cells), suicidal emperipolesis (autoreactive CD8+ T cells)
and enclysis (CD4+ T cells, Treg) have been reported for non-neoplastic hepatocytes. Neoplastic hepatocytes can also perform efferocytosis and enclysis, and
engulf fellow cancer cells that detached from matrix by entosis.
Consequences of viable cell internalization include eventual
death of host or target cells, target cell division or release, or
prevention of host cell division which can cause multinucleation,
polyploidy and aneuploidy (19, 77). This has implications for
cancer metastatic potential (78), and links between aneuploidy
and genomic instability (loss of tumor suppressor genes) have
been established (19, 77). A recent study has shown that p53
mutations in lung adenocarcinoma patients are associated with
increased incidence of cell-in-cell structures, and that mutant
p53 expression promotes entotic engulfment, tumorigenesis
and disease recurrence (51). Whilst host cells lacking p53
had perturbed cell division and subsequent death, mutant p53
cells underwent aberrant cell division, multinucleation, and
tripolar mitosis. Thus, p53 expression facilitated pro-tumorigenic
entotic engulfment and abnormal mitosis, which consequently
contributed to genomic instability.
Cell-in-cell structures in patients are indicative of worse
clinical grade and poor prognosis (51, 58, 79). In the context of
the liver, ploidy changes and multinucleation in hepatocytes are
important considerations for liver regeneration (25–27, 80–82)
and associate with various pathological processes (83). In a study
where oxidative stress was shown to promote polyploidy in non-
alcoholic fatty liver disease, the authors suggested that hepatocyte
multinucleation preceded the onset of hepatocellular carcinoma
(84). In the absence of cancer, it is now understood that the
polyploid state in mice may restrict hepatocyte proliferation and
liver regeneration (81).
It is important to consider the biological impact of cell-
in-cell structures in liver diseases. Hepatocytes have evolved
to eliminate apoptotic and necrotic cells efficiently to prevent
inflammation, and this is also true for other CIC processes,
the mechanisms of cell death in the liver have been described
previously (85, 86). Failure to eliminate necrotic or autoreactive
cells would exacerbate liver injury and increase the incidence of
fibrosis. Fibrosis (liver scarring) is the consequence of various
chronic liver diseases caused by viral, autoimmune, metabolic or
cholestatic liver injury, and can lead to cirrhosis and end-stage
disease requiring a transplant. The precise mechanism of bile acid
hepatotoxicity has not been fully elucidated.
Non-alcoholic fatty liver disease (NAFLD) is of increasing
concern at a global scale, and up to 25% of patients can progress
to non-alcoholic steatohepatitis (NASH). Increased liver enzymes
denote hepatocellular damage [ALT, AST, and others, reviewed
in (86)]. The molecular mechanisms controlling hepatocellular
injury have begun to emerge in recent studies that revealed a
role for the transcription regulator TAZ in preventing hepatocyte
death, inflammation and fibrosis (87, 88). Further, hepatocyte
Notch activation was linked directly to NASH-related fibrosis
(89). The role of efferocytosis in the clearance of apoptotic cells
and the prevention of necrotic cell injury and fibrosis in NASH
has been reviewed recently (90).
The pro- or anti-inflammatory impact of enclysis in NASH
remains to be established, however, NASH liver explants show
measurable CD4+ T cells inside hepatocytes, including FOXP3+
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and Tbet+ T cells (13). Of note, Ma et al. showed that in
NAFLD, dysregulation of lipid metabolism causes a selective
loss of intrahepatic CD4+ but not CD8+ T cells, leading to
impaired tumor surveillance and accelerated carcinogenesis (91).
The mechanism of CD4+ T cell elimination in this context
has not been described, however, it was shown that T cells
died by apoptosis following linoleic acid exposure from lipid-
laden hepatocytes.
CONCLUSION
The engulfment of live, apoptotic and necrotic cells by
hepatocytes has important implications for their biology in
health, inflammation and cancer. These range from nutrient
acquisition that can promote cancer cell survival in poorly
vascularized tumors, to changes in ploidy that can affect liver
regeneration and cancer aggressiveness. It is therefore important
to understand the molecular mechanisms that govern these
processes so that they can be targeted specifically for patient
benefit. Figure 5 summarizes our current knowledge of cell-in-
cell structures linked to hepatocyte biology.
Increasing the clearance or necrotic cells is an important
goal to prevent inflammation and liver failure, including in
catastrophic drug-induced liver injury such as paracetamol
(acetaminophen) toxicity. Modulation of T cell capture by
suicidal emperipolesis (CD8+ T cells) or enclysis (Treg cells) has
the potential to influence liver tolerance and toggle inflammation
in conditions such as autoimmune hepatitis, viral infection
or liver cancer, where the unmet clinical needs are profound.
We propose that understanding CIC structure mechanisms will
enable specific therapeutic targeting and has the potential to
provide new therapeutic targets for liver diseases and liver cancer.
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